Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).

Sharpley FA. et al, (2020), Br j haematol

Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.

Gooding S. et al, (2020), Blood

Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes.

Djebbari F. et al, (2020), Eur j haematol

Gremlin 1 - small protein, big impact: the multiorgan consequences of disrupted BMP antagonism†.

Gooding S. and Leedham SJ., (2020), J pathol

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.

Gooding S. et al, (2019), Nat commun, 10

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.

Olechnowicz SWZ. et al, (2019), Sci rep, 9

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.

Pasricha S-R. et al, (2017), Nat commun, 8

New approaches to targeting the bone marrow microenvironment in multiple myeloma.

Gooding S. and Edwards CM., (2016), Curr opin pharmacol, 28, 43 - 49

Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders

Anzilotti C. et al, (2015), Journal of allergy and clinical immunology, 136, 487 - 490.e2

Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders.

Anzilotti C. et al, (2015), J allergy clin immunol, 136, 487 - 90.e2

Managing multiple myeloma in the over 70s: a review.

King AJ. et al, (2015), Maturitas, 80, 148 - 154

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Gooding S. et al, (2015), Plos one, 10

Managing multiple myeloma in the over 70s: A review

King AJ. et al, (2015), Maturitas, 80, 148 - 154

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Eyre TA. et al, (2014), Int j hematol, 99, 798 - 800

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect

Eyre TA. et al, (2014), International journal of hematology, 99, 798 - 800

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

Fisher SA. et al, (2013), Cochrane database of systematic reviews

Oral deferiprone for iron chelation in people with thalassaemia.

Fisher SA. et al, (2013), Cochrane database syst rev

Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis.

Millington KA. et al, (2010), J infect dis, 202, 1685 - 1689

MicroRNA expression in chronic lymphocytic leukaemia.

Lawrie CH. et al, (2009), Br j haematol, 147, 398 - 402

Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice.

Gooding S. et al, (2007), J infect, 54, e169 - e174

Include forthcoming?